Annual CFO
-$30.14 M
-$910.00 K-3.11%
December 31, 2023
Summary
- As of February 7, 2025, TCRT annual cash flow from operations is -$30.14 million, with the most recent change of -$910.00 thousand (-3.11%) on December 31, 2023.
- During the last 3 years, TCRT annual CFO has risen by +$26.87 million (+47.13%).
- TCRT annual CFO is now -301320.00% below its all-time high of -$10.00 thousand, reached on December 31, 2015.
Performance
TCRT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$781.00 K
+$900.00 K+53.54%
September 30, 2024
Summary
- As of February 7, 2025, TCRT quarterly cash flow from operations is -$781.00 thousand, with the most recent change of +$900.00 thousand (+53.54%) on September 30, 2024.
- Over the past year, TCRT quarterly CFO has increased by +$900.00 thousand (+53.54%).
- TCRT quarterly CFO is now -101.73% below its all-time high of $45.20 million, reached on September 30, 2015.
Performance
TCRT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$11.76 M
+$5.59 M+32.22%
September 30, 2024
Summary
- As of February 7, 2025, TCRT TTM cash flow from operations is -$11.76 million, with the most recent change of +$5.59 million (+32.22%) on September 30, 2024.
- Over the past year, TCRT TTM CFO has increased by +$5.59 million (+32.22%).
- TCRT TTM CFO is now -184.50% below its all-time high of $13.92 million, reached on September 30, 2015.
Performance
TCRT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
TCRT Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -3.1% | +53.5% | +32.2% |
| 3 y3 years | +47.1% | +91.8% | +81.4% |
| 5 y5 years | +39.0% | +95.1% | +77.2% |
TCRT Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -3.1% | +51.0% | at high | +94.8% | at high | +80.9% |
| 5 y | 5-year | -3.1% | +51.0% | at high | +96.4% | at high | +83.2% |
| alltime | all time | <-9999.0% | +61.8% | -101.7% | +97.0% | -184.5% | +85.1% |
Alaunos Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$781.00 K(-53.5%) | -$11.76 M(-32.2%) |
| Jun 2024 | - | -$1.68 M(-12.3%) | -$17.36 M(-23.5%) |
| Mar 2024 | - | -$1.92 M(-74.0%) | -$22.68 M(-24.8%) |
| Dec 2023 | -$30.14 M(+3.1%) | -$7.38 M(+15.9%) | -$30.14 M(+0.9%) |
| Sep 2023 | - | -$6.37 M(-9.0%) | -$29.89 M(+0.8%) |
| Jun 2023 | - | -$7.00 M(-25.4%) | -$29.66 M(-3.8%) |
| Mar 2023 | - | -$9.38 M(+31.6%) | -$30.84 M(+5.5%) |
| Dec 2022 | -$29.23 M(-52.4%) | -$7.13 M(+16.0%) | -$29.23 M(-21.5%) |
| Sep 2022 | - | -$6.14 M(-24.9%) | -$37.23 M(-8.4%) |
| Jun 2022 | - | -$8.19 M(+5.4%) | -$40.66 M(-24.6%) |
| Mar 2022 | - | -$7.77 M(-48.6%) | -$53.92 M(-12.3%) |
| Dec 2021 | -$61.47 M(+7.8%) | -$15.13 M(+57.9%) | -$61.47 M(-3.0%) |
| Sep 2021 | - | -$9.58 M(-55.4%) | -$63.38 M(-9.3%) |
| Jun 2021 | - | -$21.45 M(+40.1%) | -$69.87 M(+11.9%) |
| Mar 2021 | - | -$15.31 M(-10.1%) | -$62.42 M(+9.5%) |
| Dec 2020 | -$57.01 M(+39.6%) | -$17.04 M(+6.0%) | -$57.01 M(+10.5%) |
| Sep 2020 | - | -$16.07 M(+14.7%) | -$51.59 M(+11.1%) |
| Jun 2020 | - | -$14.01 M(+41.4%) | -$46.45 M(+14.6%) |
| Mar 2020 | - | -$9.91 M(-14.7%) | -$40.53 M(-0.8%) |
| Dec 2019 | -$40.85 M(-17.4%) | -$11.61 M(+6.2%) | -$40.85 M(-0.5%) |
| Sep 2019 | - | -$10.93 M(+35.1%) | -$41.06 M(+6.3%) |
| Jun 2019 | - | -$8.09 M(-21.0%) | -$38.65 M(-5.1%) |
| Mar 2019 | - | -$10.23 M(-13.4%) | -$40.73 M(-17.6%) |
| Dec 2018 | -$49.46 M(-9.5%) | -$11.82 M(+38.9%) | -$49.46 M(-0.7%) |
| Sep 2018 | - | -$8.51 M(-16.4%) | -$49.79 M(-7.8%) |
| Jun 2018 | - | -$10.17 M(-46.3%) | -$54.00 M(-9.0%) |
| Mar 2018 | - | -$18.96 M(+55.9%) | -$59.35 M(+8.6%) |
| Dec 2017 | -$54.67 M(-6.3%) | -$12.16 M(-4.4%) | -$54.67 M(-1.6%) |
| Sep 2017 | - | -$12.71 M(-18.1%) | -$55.58 M(-2.5%) |
| Jun 2017 | - | -$15.52 M(+8.7%) | -$56.97 M(+0.8%) |
| Mar 2017 | - | -$14.28 M(+9.3%) | -$56.52 M(-3.1%) |
| Dec 2016 | -$58.33 M(>+9900.0%) | -$13.06 M(-7.4%) | -$58.33 M(-15.5%) |
| Sep 2016 | - | -$14.11 M(-6.4%) | -$69.06 M(+608.3%) |
| Jun 2016 | - | -$15.07 M(-6.3%) | -$9.75 M(+53.0%) |
| Mar 2016 | - | -$16.08 M(-32.4%) | -$6.37 M(>+9900.0%) |
| Dec 2015 | -$10.00 K(-100.0%) | -$23.80 M(-152.7%) | -$10.00 K(-100.1%) |
| Sep 2015 | - | $45.20 M(-486.5%) | $13.92 M(-133.3%) |
| Jun 2015 | - | -$11.69 M(+20.3%) | -$41.77 M(+10.8%) |
| Mar 2015 | - | -$9.72 M(-1.6%) | -$37.71 M(+2.9%) |
| Dec 2014 | -$36.65 M(-38.4%) | -$9.87 M(-5.9%) | -$36.65 M(+2.3%) |
| Sep 2014 | - | -$10.49 M(+37.4%) | -$35.83 M(-12.3%) |
| Jun 2014 | - | -$7.63 M(-11.8%) | -$40.83 M(-18.2%) |
| Mar 2014 | - | -$8.65 M(-4.3%) | -$49.92 M(-16.1%) |
| Dec 2013 | -$59.51 M(-24.5%) | -$9.04 M(-41.6%) | -$59.51 M(-17.3%) |
| Sep 2013 | - | -$15.50 M(-7.3%) | -$71.96 M(+1.1%) |
| Jun 2013 | - | -$16.72 M(-8.3%) | -$71.17 M(-0.1%) |
| Mar 2013 | - | -$18.24 M(-15.1%) | -$71.22 M(-9.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | -$78.83 M(+103.0%) | -$21.50 M(+46.2%) | -$78.83 M(+10.9%) |
| Sep 2012 | - | -$14.71 M(-12.3%) | -$71.08 M(+5.4%) |
| Jun 2012 | - | -$16.77 M(-35.2%) | -$67.47 M(+19.4%) |
| Mar 2012 | - | -$25.86 M(+88.1%) | -$56.53 M(+45.6%) |
| Dec 2011 | -$38.84 M(+97.2%) | -$13.75 M(+23.9%) | -$38.84 M(+25.8%) |
| Sep 2011 | - | -$11.10 M(+90.6%) | -$30.87 M(+20.7%) |
| Jun 2011 | - | -$5.82 M(-28.7%) | -$25.58 M(+6.3%) |
| Mar 2011 | - | -$8.17 M(+41.2%) | -$24.07 M(+22.2%) |
| Dec 2010 | -$19.69 M(+60.2%) | -$5.78 M(-0.4%) | -$19.69 M(+13.8%) |
| Sep 2010 | - | -$5.81 M(+34.6%) | -$17.30 M(+27.6%) |
| Jun 2010 | - | -$4.32 M(+13.9%) | -$13.56 M(+18.2%) |
| Mar 2010 | - | -$3.79 M(+11.7%) | -$11.47 M(-6.7%) |
| Dec 2009 | -$12.29 M(-47.7%) | -$3.39 M(+64.2%) | -$12.29 M(-3.2%) |
| Sep 2009 | - | -$2.07 M(-7.1%) | -$12.71 M(-23.1%) |
| Jun 2009 | - | -$2.23 M(-51.7%) | -$16.53 M(-20.0%) |
| Mar 2009 | - | -$4.61 M(+21.2%) | -$20.66 M(-12.2%) |
| Dec 2008 | -$23.52 M(+8.6%) | -$3.80 M(-35.4%) | -$23.52 M(-7.8%) |
| Sep 2008 | - | -$5.89 M(-7.2%) | -$25.52 M(+1.4%) |
| Jun 2008 | - | -$6.35 M(-15.0%) | -$25.17 M(+2.1%) |
| Mar 2008 | - | -$7.47 M(+28.7%) | -$24.66 M(+13.9%) |
| Dec 2007 | -$21.65 M(+50.1%) | -$5.80 M(+4.6%) | -$21.65 M(-0.4%) |
| Sep 2007 | - | -$5.55 M(-5.0%) | -$21.75 M(+15.7%) |
| Jun 2007 | - | -$5.84 M(+30.9%) | -$18.79 M(+20.1%) |
| Mar 2007 | - | -$4.46 M(-24.4%) | -$15.65 M(+8.5%) |
| Dec 2006 | -$14.42 M(+64.2%) | -$5.90 M(+127.8%) | -$14.42 M(+39.8%) |
| Sep 2006 | - | -$2.59 M(-4.0%) | -$10.32 M(+2.2%) |
| Jun 2006 | - | -$2.70 M(-16.5%) | -$10.09 M(-9.3%) |
| Mar 2006 | - | -$3.23 M(+80.1%) | -$11.12 M(+26.7%) |
| Dec 2005 | -$8.78 M(+143.8%) | -$1.79 M(-24.2%) | -$8.78 M(+9.4%) |
| Sep 2005 | - | -$2.37 M(-36.6%) | -$8.02 M(-2.3%) |
| Jun 2005 | - | -$3.73 M(+320.2%) | -$8.21 M(+83.0%) |
| Mar 2005 | - | -$888.10 K(-14.5%) | -$4.49 M(+24.6%) |
| Dec 2004 | -$3.60 M(+3589.5%) | -$1.04 M(-59.4%) | -$3.60 M(+35.9%) |
| Sep 2004 | - | -$2.56 M(>+9900.0%) | -$2.65 M(+2707.9%) |
| Jun 2004 | - | -$4600.00(+228.6%) | -$94.40 K(-4.6%) |
| Mar 2004 | - | -$1400.00(-98.4%) | -$99.00 K(+1.3%) |
| Dec 2003 | -$97.60 K(+727.1%) | -$88.30 K(>+9900.0%) | -$97.70 K(+1202.7%) |
| Sep 2003 | - | -$100.00(-98.9%) | -$7500.00(-16.7%) |
| Jun 2003 | - | -$9200.00(+9100.0%) | -$9000.00(+57.9%) |
| Mar 2003 | - | -$100.00(-105.3%) | -$5700.00(-51.3%) |
| Dec 2002 | -$11.80 K(-61.1%) | $1900.00(-218.8%) | -$11.70 K(-35.0%) |
| Sep 2002 | - | -$1600.00(-72.9%) | -$18.00 K(-15.9%) |
| Jun 2002 | - | -$5900.00(-3.3%) | -$21.40 K(-18.0%) |
| Mar 2002 | - | -$6100.00(+38.6%) | -$26.10 K(-13.9%) |
| Dec 2001 | -$30.30 K | -$4400.00(-12.0%) | -$30.30 K(+17.0%) |
| Sep 2001 | - | -$5000.00(-52.8%) | -$25.90 K(+23.9%) |
| Jun 2001 | - | -$10.60 K(+2.9%) | -$20.90 K(+102.9%) |
| Mar 2001 | - | -$10.30 K | -$10.30 K |
FAQ
- What is Alaunos Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Alaunos Therapeutics?
- What is Alaunos Therapeutics annual CFO year-on-year change?
- What is Alaunos Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Alaunos Therapeutics?
- What is Alaunos Therapeutics quarterly CFO year-on-year change?
- What is Alaunos Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Alaunos Therapeutics?
- What is Alaunos Therapeutics TTM CFO year-on-year change?
What is Alaunos Therapeutics annual cash flow from operations?
The current annual CFO of TCRT is -$30.14 M
What is the all time high annual CFO for Alaunos Therapeutics?
Alaunos Therapeutics all-time high annual cash flow from operations is -$10.00 K
What is Alaunos Therapeutics annual CFO year-on-year change?
Over the past year, TCRT annual cash flow from operations has changed by -$910.00 K (-3.11%)
What is Alaunos Therapeutics quarterly cash flow from operations?
The current quarterly CFO of TCRT is -$781.00 K
What is the all time high quarterly CFO for Alaunos Therapeutics?
Alaunos Therapeutics all-time high quarterly cash flow from operations is $45.20 M
What is Alaunos Therapeutics quarterly CFO year-on-year change?
Over the past year, TCRT quarterly cash flow from operations has changed by +$900.00 K (+53.54%)
What is Alaunos Therapeutics TTM cash flow from operations?
The current TTM CFO of TCRT is -$11.76 M
What is the all time high TTM CFO for Alaunos Therapeutics?
Alaunos Therapeutics all-time high TTM cash flow from operations is $13.92 M
What is Alaunos Therapeutics TTM CFO year-on-year change?
Over the past year, TCRT TTM cash flow from operations has changed by +$5.59 M (+32.22%)